The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

Cancer Management and Research

Volumn 6, Issue , 2014, Pages 373-387

  Poulsen, Hans Skovgaard ^a   Urup, Thomas ^a   Michaelsen, Signe Regner ^a   Staberg, Mikkel ^a   Villingshøj, Mette ^a   Lassen, Ulrik ^a,b  

^a Mental Health Services CPH   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Monoclonal antibody; Patient survival; Primary treatment; Quality of life; Vascular tumor; VEGF

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; FOTEMUSTINE; IRINOTECAN; PLACEBO; TEMOZOLOMIDE; VASCULOTROPIN A;

ANEMIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL ABSCESS; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MUCOCUTANEOUS BLEEDING; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NEUTROPENIA; NEUTROPENIC SEPSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SKIN BLEEDING; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

EID: 84907512411     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S39306     Document Type: Review

References (110)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-996.
2. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-1027.
3. Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 2012;124(6):763-775.
4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62.
5. Batchelor TT, Gerstner ER, Emblem KE et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 2013;110(47):19059-19064.
6. de Groot JF, Mandel JJ. Update on anti-angiogenic treatment for malignant gliomas. Curr Oncol Rep 2014;16(4):380.
7. Han K, Ren M, Wick W et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol 2014;16(5):696-706.
8. Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 2011;104(3):639-646.
9. Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother 2011;12(5):825-833.
10. Olson JJ, Nayak L, Ormond DR, et al. The role of targeted therapies in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline. J Neurooncol 2014.
11. Chauffert B, Feuvret L, Bonnetain F et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared to temozolomide-chemoradiation for unresectable glioblastoma. Final results of the TEMAVIR study from ANOCEF. Ann Oncol 2014.
12. Hofland KF, Hansen S, Sorensen M et al. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Acta Oncol 2014.
13. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011;29(2):142-148.
14. Lou E, Peters KB, Sumrall AL et al. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med 2013;2(2):185-195.
15. Narayana A, Gruber D, Kunnakkat S et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 2012;116(2):341-345.
16. Omuro A, Beal K, Gutin P, et al. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clin Cancer Res. Epub August 8 2014.
17. Vredenburgh JJ, Desjardins A, Reardon DA et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011;17(12):4119-4124.
18. Chinot OL, Wick W, Mason W et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709-722.
19. Gilbert MR, Dignam JJ, Armstrong TS et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):699-708.
20. Herrlinger, U, Schäfer, N, Steinbach, JP et al. Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients. J Clin Oncol. May 31, 2014;32(5s):(suppl; abstr 2042).
21. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-1186.
22. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007;13(35):3545-3558.
23. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603.
24. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15(14):4589-4599.
25. Piao Y, Liang J, Holmes L et al. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013;19(16):4392-4403.
26. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-989.
27. Chae SS, Kamoun WS, Farrar CT et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16(14):3618-3627.
28. Goel S, Duda DG, Xu L et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91(3):1071-1121.
29. McGee MC, Hamner JB, Williams RF et al. Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010;76(5):1537-1545.
30. Winkler F, Kozin SV, Tong RT et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6(6):553-563.
31. Hamerlik P, Lathia JD, Rasmussen R et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med 2012;209(3):507-520.
32. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-4740.
33. Michaelsen SR, Christensen IJ, Grunnet K et al. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer 2013;13:402.
34. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003.
35. Gilbert MR, Wang M, Aldape KD et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31(32):4085-4091.
36. Bloch O, Safaee M, Sun MZ et al. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 2013;115(9):1795-1801.
37. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101(2):319-323.
38. Pope WB, Xia Q, Paton VE et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76(5):432-437.
39. de Groot JF, Fuller G, Kumar AJ et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12(3):233-242.
40. Keunen O, Johansson M, Oudin A et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011;108(9):3749-3754.
41. Hasselbalch B, Eriksen JG, Broholm H et al. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010;118(8):585-594.
42. Laffaire J, Di Stefano AL, Chinot O et al. An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas. Biomed Res Int 2014;2014:282815.
43. Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26(2):271-278.
44. DeLay M, Jahangiri A, Carbonell WS et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 2012;18(10):2930-2942.
45. Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-231.
46. Jubb AM, Browning L, Campo L et al. Expression of vascular Notch ligands Delta-like 4 and Jagged-1 in glioblastoma. Histopathology 2012;60(5):740-747.
47. Lu-Emerson C, Snuderl M, Kirkpatrick ND et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol 2013;15(8):1079-1087.
48. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008;8(8):618-631.
49. Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2013;2(1):49-65.
50. Piao Y, Liang J, Holmes L et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 2012;14(11):1379-1392.
51. Shojaei F, Wu X, Zhong C et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007;450(7171):825-831.
52. Janbazian L, Karamchandani J, Das S. Mouse models of glioblastoma: lessons learned and questions to be answered. J Neurooncol 2014;118(1):1-8.
53. Jahangiri A, De LM, Miller LM et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013;19(7):1773-1783.
54. Lu KV, Chang JP, Parachoniak CA et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22(1):21-35.
55. Francescone R, Scully S, Bentley B et al. Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem 2012;287(29):24821-24831.
56. Yao X, Ping Y, Liu Y et al. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stem-like cells. PLoS One 2013;8(3):e57188.
57. Lampson LA. Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs 2011;3(2):153-160.
58. Phillips, H, Sandman, T, Li, C et al. Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]). J Clin Oncol. 2014;32(5):(suppl; abstr 2001).
59. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157-173.
60. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110.
61. Wong ET, Gautam S, Malchow C et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011;9(4):403-407.
62. Anderson MD, Hamza MA, Hess KR, Puduvalli VK. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol 2014;16(6):823-828.
63. Armstrong TS, Wen PY, Gilbert MR, Schiff D. Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. Neuro Oncol 2012;14(10):1203-1214.
64. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-1280.
65. Reardon DA, Galanis E, DeGroot JF et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 2011;13(3):353-361.
66. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-1972.
67. Finn MA, Blumenthal DT, Salzman KL, Jensen RL. Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 2007;67(3):246-250.
68. Henegar MM, Moran CJ, Silbergeld DL. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. J Neurosurg 1996;84(2):174-179.
69. Kumar AJ, Leeds NE, Fuller GN et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217(2):377-384.
70. Ulmer S, Braga TA, Barker FG et al. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006;67(9):1668-1670.
71. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9(5):453-461.
72. Chamberlain MC, Glantz MJ, Chalmers L, Van HA, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007;82(1):81-83.
73. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63(3):535-537.
74. Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
75. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008;29(3):419-424.
76. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008;5(11):634-644.
77. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria. J Clin Oncol 2009;27(18):2905-2908.
78. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-4729.
79. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 2011;32(11):1978-1985.
80. Chinot OL, Macdonald DR, Abrey LE et al. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep 2013;13(5):347.
81. Gallego Perez-Larraya J, Lahutte M, Petrirena G et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012;14(5):667-673.
82. Colavolpe C, Chinot O, Metellus P et al. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 2012;14(5):649-657.
83. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 1995;58(2):250-252.
84. Corroyer-Dulmont A, Peres EA, Petit E et al. Detection of glioblastoma response to temozolomide combined with bevacizumab based on muMRI and muPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy. Neuro Oncol 2013;15(1):41-56.
85. Nedergaard MK, Kristoffersen K, Michaelsen SR et al. The Use of Longitudinal 18F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts. PLoS One 2014;9(2):e100009.
86. Galldiks N, Rapp M, Stoffels G et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2013;40(1):22-33.
87. Brandes AA, Franceschi E, Gorlia T et al. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 2012;48(6):896-903.
88. Norden AD, Drappatz J, Muzikansky A et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009;92(2):149-155.
89. Taphoorn MJ, Klein M. Evaluation of cognitive functions and quality of life. Handb Clin Neurol 2012;104:173-183.
90. Bosma I, Vos MJ, Heimans JJ et al. The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol 2007;9(1):53-62.
91. Meyers CA, Scheibel RS. Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park) 1990;4(7):115-122.
92. de Vries MA, van Litsenburg RR, Huisman J et al. Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study. Health Qual Life Outcomes 2008;6:103.
93. Lupien SJ, Gillin CJ, Hauger RL. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: a dose-response study in humans. Behav Neurosci 1999;113(3):420-430.
94. Young AH, Sahakian BJ, Robbins TW, Cowen PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl) 1999;145(3):260-266.
95. Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 2002;10(4):322-328.
96. Sturdza A, Millar BA, Bana N et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008;16(9):1041-1048.
97. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112(10):2267-2273.
98. Desjardins A, Reardon DA, Herndon JE et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14(21):7068-7073.
99. Guiu S, Taillibert S, Chinot O et al. [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Rev Neurol (Paris) 2008;164(6-7):588-594.
100. Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72(14):1217-1222.
101. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779-787.
102. Burger PC, Dubois PJ, Schold SC, Jr. et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983;58(2):159-169.
103. Chang EL, Akyurek S, Avalos T et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 2007;68(1):144-150.
104. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30(9):907-911.
105. Levin VA, Crafts DC, Norman DM et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 1977;47(3):329-335.
106. Iwamoto FM, Abrey LE, Beal K et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73(15):1200-1206.
107. Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110(1):173-180.
108. Wick A, Dorner N, Schafer N et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011;69(3):586-592.
109. Soffietti R, Trevisan E, Bertero L et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 2014;116(3):533-541.
110. Desjardins A, Reardon DA, Coan A et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012;118(5):1302-1312.